Jefferies Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
Tweet Send to a Friend
Jefferies analyst Dennis Ding reiterated a Buy rating and $45.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
